|
A Peptide Approach to Block eNOS Phosphorylation at T495
This invention is a peptide that blocks eNOS phosphorylation. These peptides are designed to target the T495 phosporylation site of eNOS to prevent the activation of eNOS that leads to superoxide production and overwhelming inflammation. The initial peptide has been shown to reduce NOS derived superoxide and cell barrier loss throughout trials.
Background:
Pulmonary...
Published: 6/6/2024
|
Inventor(s): Stephen Black, Evgeny Zemskov, Qing Lu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Life Sciences > Biologics
|
|
Advanced Engineered Formulations of Simvastatin and L-Carnitine Microparticle/Nanoparticle Formulations for Inhalation Drug Delivery for Respiratory and Pulmonary Vascular Diseases and Applications Therein
This invention is novel dry powder formulations of simvastatin and L-Carnitine (separately or combined) for inhalation delivery for pulmonary vascular diseases.
Background:
Pulmonary vascular diseases are caused by various reasons and may require combined therapies that act through difference mechanisms. Simvastatin inhibits undesired cholesterol...
Published: 7/26/2024
|
Inventor(s): Heidi Mansour, Stephen Black, Maria Acosta
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Life Sciences > Drug Delivery, Technology Classifications > Life Sciences > Therapeutics
|
|
Advanced Engineered Formulations Of Rho/Rock Kinase Inhibitor (fasudil) Microparticle/Nanoparticle Formulations For Inhalation Drug Delivery For Respiratory And Pulmonary Vascular Diseases And Applications Therein
This technology is the reformulation of fasudil, a known pharmaceutical, into a dry powder form to facilitate non-invasive, aerosolized administration of the medication. This affords a localized, potent and increased availability of the drugs to the body. The intended purpose of this formulation is to treat pulmonary hypertension and other pulmonary...
Published: 7/26/2024
|
Inventor(s): Heidi Mansour, Stephen Black, Priyadarshini Muralidharan
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Life Sciences > Drug Delivery
|
